Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

Inclusion Criteria: * Received an Allogeneic hematologic stem cell transplantation at least 3 months prior. * Subjects with post Allogeneic hematologic stem cell transplantation onset or worsening of dry eye symptoms for at least 1 month prior. * Use of over-the-counter and/or prescription eye drops for dry eye symptoms within 1 month. * Corneal fluorescein staining score of ≥ 2 in 1 region and ≥ 1 in at least 1 other region. * Total lissamine green conjunctival staining score (according to a modified National Eye Institute grading system) of ≥ 2. Exclusion Criteria: * Clinically unstable Graft versus Host Disease (requiring a change in immunosuppressive regimen), medical condition, or laboratory abnormality * Used topical ophthalmic cyclosporine within 45 days. * Used any topical ophthalmic steroid within 2 weeks. * Used autologous serum eye drops within 2 weeks.